Results 91 to 100 of about 4,103,638 (290)

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Targeting WEE1 and asciminib suppresses ABL-tyrosine kinase inhibitor-resistant chronic myeloid leukemia cells

Discover Oncology
Background Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the uncontrolled proliferation of white blood cells. Tyrosine kinase inhibitors (TKIs) are the standard treatment; however, resistance to BCR::ABL1 mutations ...
Seiichi Okabe, Mitsuru Moriyama, Akihiko Gotoh, Daigo Akahane   +3 more
doaj   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Shifts in Mycobacterial Populations and Emerging Drug-Resistance in West and Central Africa. [PDF]

, 2014
In this study, we retrospectively analysed a total of 605 clinical isolates from six West or Central African countries (Benin, Cameroon, Central African Republic, Guinea-Conakry, Niger and Senegal). Besides spoligotyping to assign isolates to ancient and
Martin Antonio, Odin Goovaerts (138054), Martin Gninafon, Lingoupou, Fanny M, Elie Nduwamahoro (672710), Juergen Noeske (672717), Alberto Piubello (672716), Ba, Fatoumata, Cécile Uwizeye (5661748), Elie Nduwamahoro, Martin Antonio (42317), Gehre, Florian, Oumou Sow (672713), Sow, Oumou, Dissou Affolabi (470788), Kristina Fissette (672709), Gninafon, Martin, Bouke C de Jong, Sarr, Marie, Dissou Affolabi, Uwizeye, Cécile, Alberto Piubello, Mebrat Ejo, Ejo, Mebrat, de Rijk, Pim, Fanny M Lingoupou, Kristina Fissette, Merle, Corinne, Leen Rigouts (62768), Nduwamahoro, Elie, Odin Goovaerts, Mamadou Dian Barry, Barry, Mamadou Dian, Martin Gninafon (561425), Affolabi, Dissou, Goovaerts, Odin, Marie Sarr, Florian Gehre, Pim de Rijk (377868), Noeske, Juergen, Oumou Sow, Cécile Uwizeye, Fanny M. Lingoupou (672711), Piero Olliaro (35337), Fissette, Kristina, Piubello, Alberto, Corinne Merle, Florian Gehre (182718), Mamadou Dian Barry (672712), Marie Sarr (672715), Rigouts, Leen, Piero Olliaro, Fatoumata Ba, Corinne Merle (514025), Mebrat Ejo (672708), Juergen Noeske, Fatoumata Ba (672714), de Jong, Bouke C, Pim de Rijk, Bouke C de Jong (378876), Olliaro, Piero, Leen Rigouts, Antonio, Martin   +62 more
core   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

Evolution of antibiotic resistance at non-lethal drug concentrations

, 2012
Human use of antimicrobials in the clinic, community and agricultural systems has driven selection for resistance in bacteria. Resistance can be selected at antibiotic concentrations that are either lethal or non-lethal, and here we argue that selection ...
Andersson, Dan I,, Hughes, Diarmaid,
core   +1 more source

Antimicrobial drug use and resistance in Europe [PDF]

, 2008
Our study confronts the use of antimicrobial agents in ambulatory care with the resistance trends of 2 major pathogens, Streptococcus pneumoniae and Escherichia coli, in 21 European countries in 2000–2005 and explores whether the notion that ...
Grundmann, Hajo, Goossens, Herman, Ferech, Matus, Zarb, Peter, Sande-Bruinsma, Nienke van de, Verloo, Didier, Tiemersma, Edine, Monen, Jos, European Antimicrobial Resistance Surveillance System and European Surveillance of Antimicrobial Consumption Project Groups   +8 more
core   +1 more source

A Bibliometric Analysis of Drug Resistance in Pediatric Acute Lymphoblastic Leukemia

Advanced Biomedical Research
Background: Despite the improved outcomes in acute lymphoblastic leukemia (ALL), drug resistance remains a major challenge. This study provides the first overview of global research trends in pediatric ALL drug resistance, highlighting emerging ...
Alireza Khanahmad, Mohammad Hossein Khazaee-Nasirabadi, Mahshid Lotfi, Amir Hami   +3 more
doaj   +1 more source

Imatinib Mesylate: Past Successes and Future Challenges in the Treatment of Gastrointestinal Stromal Tumors

Clinical Medicine Insights: Oncology, 2011
Just over a decade ago, gastrointestinal tumours were a poorly understood mesenchymal neoplasm unsuccessfully treated with chemotherapy. Cytotoxic therapy for advanced disease yielded response rates of 10% and median survival of just 18 months.
Doran Ksienski
doaj   +1 more source